Robert W Milne

List of Publications by Year
in descending order

83 papers	5,291 citations	117625 34 h-index	82547 72 g-index
85 all docs	85 docs citations	85 times ranked	5487 citing authors

#	Article	IF	Citations
1	Liposomal 5-Fluorouracil Polymer Complexes Facilitate Tumor-Specific Delivery: Pharmaco-Distribution Kinetics Using Microdialysis. Pharmaceutics, 2022, 14, 221.	4.5	4
2	An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia. Cancers, 2022, 14, 1113.	3.7	6
3	Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation. European Journal of Medicinal Chemistry, 2021, 214, 113248.	5.5	13
4	CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents. Frontiers in Oncology, 2021, 11, 678559.	2.8	62
5	A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer. Gynecologic Oncology, 2020, 159, 827-838.	1.4	9
6	Targeting CDK9 for treatment of colorectal cancer. Molecular Oncology, 2019, 13, 2178-2193.	4.6	39
7	Sulfonamide-Based Inhibitors of Biotin Protein Ligase as New Antibiotic Leads. ACS Chemical Biology, 2019, 14, 1990-1997.	3.4	5
8	Bioanalysis and Stability of Polymyxins. Advances in Experimental Medicine and Biology, 2019, 1145, 73-87.	1.6	5
9	Discovery of CDK5 Inhibitors through Structure-Guided Approach. ACS Medicinal Chemistry Letters, 2019, 10, 786-791.	2.8	18
10	CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia. Investigational New Drugs, 2019, 37, 625-635.	2.6	26
11	Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity. Medicinal Chemistry, 2019, 15, 602-623.	1.5	7
12	Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclinâ€dependent kinases 4 and 6 as anticancer agents. British Journal of Pharmacology, 2018, 175, 2399-2413.	5.4	18
13	Enantioselectivity in the tissue distribution of perhexiline contributes to different effects on hepatic histology and peripheral neural function in rats. Pharmacology Research and Perspectives, 2018, 6, e00406.	2.4	3
14	Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation. Journal of Medicinal Chemistry, 2017, 60, 1892-1915.	6.4	55
15	Effect of Garlic, Gingko, and St. Johnâ€™s Wort Extracts on the Pharmacokinetics of Fexofenadine: A Mechanistic Study. Drug Metabolism and Disposition, 2017, 45, 569-575.	3.3	8
16	CDK5 in oncology: recent advances and future prospects. Future Medicinal Chemistry, 2017, 9, 1939-1962.	2.3	36
17	Dual Inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia. European Journal of Medicinal Chemistry, 2017, 139, 762-772.	5.5	23
18	The association between total phthalate concentration and non-communicable diseases and chronic inflammation in South Australian urban dwelling men. Environmental Research, 2017, 158, 366-372.	7.5	35

#	Article	IF	Citations
19	Targeting CDK9: a promising therapeutic opportunity in prostate cancer. Endocrine-Related Cancer, 2016, 23, T211-T226.	3.1	57
20	Unveiling new chemical scaffolds as Mnk inhibitors. Future Medicinal Chemistry, 2016, 8, 271-285.	2.3	18
21	Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells. Oncotarget, 2016, 7, 56811-56825.	1.8	20
22	The Association of Socio-Demographic Status, Lifestyle Factors and Dietary Patterns with Total Urinary Phthalates in Australian Men. PLoS ONE, 2015, 10, e0122140.	2.5	26
23	Targeting Pim kinases for cancer treatment: opportunities and challenges. Future Medicinal Chemistry, 2015, 7, 35-53.	2.3	35
24	Comparison of CYP2D metabolism and hepatotoxicity of the myocardial metabolic agent perhexiline in Sprague€“Dawley and Dark Agouti rats. Xenobiotica, 2015, 45, 3-9.	1.1	3
25	MAP Kinase-Interacting Kinases€”Emerging Targets against Cancer. Chemistry and Biology, 2014, 21, 441-452.	6.0	83
26	Discovery of 5€(2€(Phenylamino)pyrimidin€4€yl)thiazol€2(3H)€one Derivatives as Potent Mnk2 Inhibitors: Synthesis, SAR Analysis and Biological Evaluation. ChemMedChem, 2014, 9, 962-972.	3.2	67
27	Cohort Profile: The Men Androgen Inflammation Lifestyle Environment and Stress (MAILES) Study. International Journal of Epidemiology, 2014, 43, 1040-1053.	1.9	53
28	Discovery of (E)-3-((Styrylsulfonyl)methyl)pyridine and (E)-2-((Styrylsulfonyl)methyl)pyridine Derivatives as Anticancer Agents: Synthesis, Structure€“Activity Relationships, and Biological Activities. Journal of Medicinal Chemistry, 2014, 57, 2275-2291.	6.4	23
29	Chiral Stability Study of Oral Liquid Clopidogrel Formulations for Infants. Journal of Pharmacy Practice and Research, 2012, 42, 106-110.	0.8	2
30	Stability of Myrmecia pilosula (Jack Jumper) Ant venom for use in immunotherapy. Journal of Pharmaceutical and Biomedical Analysis, 2011, 54, 303-310.	2.8	12
31	PHARMACOKINETICS OF MOXIDECTIN IN THE SOUTHERN HAIRY-NOSED WOMBAT (LASIORHINUS LATIFRONS). Journal of Wildlife Diseases, 2011, 47, 643-649.	0.8	18
32	The effects of the phytoestrogenic isoflavone genistein on the hepatic disposition of preformed and hepatically generated gemfibrozil 1-O-acyl glucuronide in the isolated perfused rat liver. Journal of Pharmacy and Pharmacology, 2010, 55, 1433-1439.	2.4	1
33	Effect of ketoprofen and its enantiomers on the renal disposition of methotrexate in the isolated perfused rat kidney. Journal of Pharmacy and Pharmacology, 2010, 55, 1641-1646.	2.4	9
34	The effects of phytoestrogenic isoflavones on the formation and disposition of paracetamol sulfate in the isolated perfused rat liver. Journal of Pharmacy and Pharmacology, 2010, 55, 639-646.	2.4	10
35	Effect of St John's wort on the disposition of fexofenadine in the isolated perfused rat liver. Journal of Pharmacy and Pharmacology, 2010, 61, 1037-1042.	2.4	0
36	Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent. British Journal of Cancer, 2010, 103, 597-606.	6.4	25

#	Article	IF	Citations
37	Inhibition of Morphine Metabolism by Ketamine. Drug Metabolism and Disposition, 2010, 38, 728-731.	3.3	27
38	Elucidation of the Pharmacokinetic/Pharmacodynamic Determinant of Colistin Activity against Pseudomonas aeruginosa in Murine Thigh and Lung Infection Models. Antimicrobial Agents and Chemotherapy, 2010, 54, 1117-1124.	3.2	178
39	Renal Disposition of Colistin in the Isolated Perfused Rat Kidney. Antimicrobial Agents and Chemotherapy, 2009, 53, 2857-2864.	3.2	68
40	Effect of St Johnâ€™s wort on the disposition of fexofenadine in the isolated perfused rat liver. Journal of Pharmacy and Pharmacology, 2009, 61, 1037-1042.	2.4	6
41	Myrmecia pilosula (Jack Jumper) ant venom: Validation of a procedure to standardise an allergy vaccine. Journal of Pharmaceutical and Biomedical Analysis, 2008, 46, 58-65.	2.8	18
42	Determination of colistin in human plasma, urine and other biological samples using LCâ€“MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 862, 205-212.	2.3	54
43	Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline. British Journal of Clinical Pharmacology, 2008, 65, 347-354.	2.4	7
44	Subacute Toxicity of Colistin Methanesulfonate in Rats: Comparison of Various Intravenous Dosage Regimens. Antimicrobial Agents and Chemotherapy, 2008, 52, 1159-1161.	3.2	67
45	Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Journal of Antimicrobial Chemotherapy, 2008, 61, 636-642.	3.0	119
46	CYP2B6, CYP2D6, and CYP3A4 Catalyze the Primary Oxidative Metabolism of Perhexiline Enantiomers by Human Liver Microsomes. Drug Metabolism and Disposition, 2007, 35, 128-138.	3.3	25
47	Effect of CYP2D6 metabolizer status on the disposition of the (+) and (â^') enantiomers of perhexiline in patients with myocardial ischaemia. Pharmacogenetics and Genomics, 2007, 17, 305-312.	1.5	10
48	Original article: Myrmecia pilosula (Jack Jumper) ant venom: identification of allergens and revised nomenclature. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 437-443.	5.7	46
49	Isosteviol reduces plasma glucose levels in the intravenous glucose tolerance test in Zucker diabetic fatty rats. Diabetes, Obesity and Metabolism, 2007, 9, 597-599.	4.4	50
50	Frequently asked questions about generic medicines. Australian Prescriber, 2007, 30, 41-43.	1.0	14
51	Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infectious Diseases, The, 2006, 6, 589-601.	9.1	1,170
52	Disposition and Metabolite Kinetics of Oral Lâ€carnitine in Humans. Journal of Clinical Pharmacology, 2006, 46, 1163-1170.	2.0	34
53	Proteomic analysis of Myrmecia pilosula (jack jumper) ant venom. Toxicon, 2006, 47, 208-217.	1.6	41
54	Enantioselective assay for the determination of perhexiline enantiomers in human plasma by liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 832, 114-120.	2.3	17

#	Article	IF	Citations
55	Determination of the 4-monohydroxy metabolites of perhexiline in human plasma, urine and liver microsomes by liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 843, 302-309.	2.3	12
56	Loading-Washout Studies of the Stereoselective Sinusoidal Uptake of (R)- and (S)-2-Phenylpropionyl Acyl Glucuronide. Current Drug Metabolism, 2006, 7, 817-826.	1.2	0
57	Oral L-Carnitine: Metabolite Formation and Hemodialysis. Current Drug Metabolism, 2006, 7, 811-816.	1.2	24
58	Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis. Nephrology Dialysis Transplantation, 2006, 21, 1300-1304.	0.7	222
59	Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. International Journal of Antimicrobial Agents, 2005, 25, 11-25.	2.5	456
60	Stereoselective Hepatic Disposition of Model Diastereomeric Acyl Glucuronides. Journal of Pharmacokinetics and Pharmacodynamics, 2004, 31, 1-27.	1.8	3
61	The quantification of paracetamol, paracetamol glucuronide and paracetamol sulphate in plasma and urine using a single high-performance liquid chromatography assay. Journal of Pharmaceutical and Biomedical Analysis, 2004, 34, 585-593.	2.8	80
62	Quantifying trimethylamine and trimethylamine-N-oxide in human plasma: interference from endogenous quaternary ammonium compounds. Analytical Biochemistry, 2004, 334, 403-405.	2.4	26
63	Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. Journal of Antimicrobial Chemotherapy, 2004, 53, 837-840.	3.0	150
64	Phenytoin Infusion Revisited: Stability and Administration. Journal of Pharmacy Practice and Research, 2004, 34, 272-275.	0.8	1
65	Use of High-Performance Liquid Chromatography To Study the Pharmacokinetics of Colistin Sulfate in Rats following Intravenous Administration. Antimicrobial Agents and Chemotherapy, 2003, 47, 1766-1770.	3.2	149
66	Stability of Colistin and Colistin Methanesulfonate in Aqueous Media and Plasma as Determined by High-Performance Liquid Chromatography. Antimicrobial Agents and Chemotherapy, 2003, 47, 1364-1370.	3.2	182
67	Cerebral and lung kinetics of morphine in conscious sheep after short intravenous infusions. British Journal of Anaesthesia, 2003, 90, 750-758.	3.4	15
68	Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. Journal of Antimicrobial Chemotherapy, 2003, 52, 987-992.	3.0	159
69	Simple Method for Assaying Colistin Methanesulfonate in Plasma and Urine Using High-Performance Liquid Chromatography. Antimicrobial Agents and Chemotherapy, 2002, 46, 3304-3307.	3.2	101
70	A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. Biomedical Applications, 2001, 761, 167-175.	1.7	131
71	A small-scale synthesis and enantiomeric resolution of (RS)-[1-14C]-2-Phenylpropionic acid and biosynthesis of its diastereomeric acyl glucuronides. Journal of Labelled Compounds and Radiopharmaceuticals, 2001, 44, 225-234.	1.0	8
72	In Vitro Pharmacodynamic Properties of Colistin and Colistin Methanesulfonate against Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis. Antimicrobial Agents and Chemotherapy, 2001, 45, 781-785.	3.2	218

#	Article	IF	Citations
73	Hepatic disposition of fexofenadine: influence of the transport inhibitors erythromycin and dibromosulphothalein. Pharmaceutical Research, 2000, 17, 1511-1515.	3.5	38
74	Organ perfusion techniques in drug development. Drug Development Research, 1999, 46, 292-301.	2.9	10
75	Comparison of the disposition of hepatically-generated morphine-3-glucuronide and morphine-6-glucuronide in isolated perfused liver from the guinea pig. Pharmaceutical Research, 1997, 14, 1014-1018.	3.5	18
76	The Disposition of Morphine and Its 3- and 6-Glucuronide Metabolites in Humans and Animals, and the Importance of the Metabolites to the Pharmacological Effects of Morphine. Drug Metabolism Reviews, 1996, 28, 345-472.	3.6	190
77	Plasma Concentrations and Renal Clearance of Morphine, Morphine-3-Glucuronide and Morphine-6-Glucuronide in Cancer Patients Receiving Morphine. Clinical Pharmacokinetics, 1993, 24, 413-420.	3.5	44
78	High-performance liquid chromatographic determination of morphine and its 3- and 6-glucuronide metabolites: improvements to the method and application to stability studies. Biomedical Applications, 1991, 565, 457-464.	1.7	78
79	PHYSIOLOGICAL DISPOSITION OF I.V. MORPHINE IN SHEEP â€. British Journal of Anaesthesia, 1991, 67, 378-386.	3.4	20
80	Pharmacokinetic Drug Interactions with Phenytoin (Part I)1. Clinical Pharmacokinetics, 1990, 18, 37-60.	3.5	112
81	Pharmacokinetic Drug Interactions with Phenytoin (Part II). Clinical Pharmacokinetics, 1990, 18, 131-150.	3.5	46
82	Moxalactam kinetics during continuous ambulatory peritoneal dialysis after intraperitoneal administration. Antimicrobial Agents and Chemotherapy, 1985, 28, 293-298.	3.2	7
83	Comparative bioavailability of a microcrystalline theophylline tablet and uncoated aminophylline tablets. European Journal of Clinical Pharmacology, 1979, 16, 417-421.	1.9	6